Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Maggi, L. B.
Right arrow Articles by Corbett, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maggi, L. B.
Right arrow Articles by Corbett, J. A.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes, Vol 49, Issue 3 346-355, Copyright © 2000 by American Diabetes Association


ARTICLES

Anti-inflammatory actions of 15-deoxy-delta 12,14-prostaglandin J2 and troglitazone: evidence for heat shock-dependent and -independent inhibition of cytokine-induced inducible nitric oxide synthase expression

LB Maggi, H Sadeghi, C Weigand, AL Scarim, MR Heitmeier and JA Corbett
Edward A. Doisy Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, Missouri 63104, USA.

In this study, the anti-inflammatory actions of the peroxisome proliferator-activated receptor (PPAR)-gamma agonists 15-deoxy-delta 12,14-prostaglandin J2 (15-d-delta 12,14-PGJ2) and troglitazone have been examined. Treatment of RAW 264.7 cells and CD-1 mouse peritoneal macrophages with lipopolysaccharide (LPS) + interferon-gamma (IFN-gamma) results in inducible nitric oxide synthase (iNOS), inducible cyclooxygenase (COX-2) and interleukin-1 (IL-1) expression, increased production of nitric oxide, and the release of IL-1. In a concentration-dependent manner, 15-d-delta 12,14-PGJ2 inhibits each of these proinflammatory actions of LPS + IFN-gamma, with half-maximal inhibition at approximately 0.5 microg/ml and complete inhibition at 1-5 microg/ml. The inhibitory actions of 15-d-delta 12,14-PGJ2 on LPS + IFN-gamma-induced inflammatory events are not associated with the inhibition of iNOS enzymatic activity or macrophage cell death, but appear to result from an inhibition of iNOS and IL-1 transcription. In addition, the anti-inflammatory actions of 15-d-delta 12,14-PGJ2 are not limited to peritoneal macrophages, as 15-d-delta 12,14-PGJ2 prevents TNF-alpha + LPS-induced resident islet macrophage expression of IL-1beta and beta-cell expression of iNOS stimulated by the local release of IL-1 in rat islets. 15-d-delta 12,14-PGJ2 appears to be approximately 10-fold more effective at inhibiting resident islet macrophage activation (in response to TNF + LPS) than IL-1-induced nitrite production by beta-cells. Two mechanisms appear to be associated with the antiinflammatory actions of both 15-d-delta 12,14-PGJ2 and troglitazone: 1) the direct inhibition of cytokine- and endotoxin-stimulated iNOS and IL-1 transcription; and 2) the inhibition of IL-1 signaling, an event associated with PPAR-gamma agonist-induced activation of the heat shock response (as assayed by heat shock protein 70 expression). These findings indicate that the PPAR-gamma agonists, troglitazone and the J series of prostaglandins, are potent anti-inflammatory agents that prevent cytokine- and endotoxin-stimulated activation of peripheral and resident tissue macrophages and cytokine-induced iNOS expression by beta-cells by the inhibition of transcriptional activation and induction of the heat shock response.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
DiabetesHome page
P. Dallaire, K. Bellmann, M. Laplante, S. Gelinas, C. Centeno-Baez, P. Penfornis, M.-L. Peyot, M. G. Latour, J. Lamontagne, M. E. Trujillo, et al.
Obese Mice Lacking Inducible Nitric Oxide Synthase Are Sensitized to the Metabolic Actions of Peroxisome Proliferator-Activated Receptor-{gamma} Agonism
Diabetes, August 1, 2008; 57(8): 1999 - 2011.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
K. T. Chambers, S. M. Weber, and J. A. Corbett
PGJ2-stimulated beta-cell apoptosis is associated with prolonged UPR activation
Am J Physiol Endocrinol Metab, April 1, 2007; 292(4): E1052 - E1061.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. Luna-Medina, M. Cortes-Canteli, M. Alonso, A. Santos, A. Martinez, and A. Perez-Castillo
Regulation of Inflammatory Response in Neural Cells in Vitro by Thiadiazolidinones Derivatives through Peroxisome Proliferator-activated Receptor {gamma} Activation
J. Biol. Chem., June 3, 2005; 280(22): 21453 - 21462.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
M. Fujimoto, N. Shimizu, K. Kunii, J.A. J. Martyn, K. Ueki, and M. Kaneki
A Role for iNOS in Fasting Hyperglycemia and Impaired Insulin Signaling in the Liver of Obese Diabetic Mice
Diabetes, May 1, 2005; 54(5): 1340 - 1348.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
M. A. Carvalho-Filho, M. Ueno, S. M. Hirabara, A. B. Seabra, J. B.C. Carvalheira, M. G. de Oliveira, L. A. Velloso, R. Curi, and M. J.A. Saad
S-Nitrosation of the Insulin Receptor, Insulin Receptor Substrate 1, and Protein Kinase B/Akt: A Novel Mechanism of Insulin Resistance
Diabetes, April 1, 2005; 54(4): 959 - 967.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
S. M. Weber, K. T. Chambers, K. G. Bensch, A. L. Scarim, and J. A. Corbett
PPAR{gamma} ligands induce ER stress in pancreatic {beta}-cells: ER stress activation results in attenuation of cytokine signaling
Am J Physiol Endocrinol Metab, December 1, 2004; 287(6): E1171 - E1177.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
O. Hofnagel, B. Luechtenborg, K. Stolle, S. Lorkowski, H. Eschert, G. Plenz, and H. Robenek
Proinflammatory Cytokines Regulate LOX-1 Expression in Vascular Smooth Muscle Cells
Arterioscler. Thromb. Vasc. Biol., October 1, 2004; 24(10): 1789 - 1795.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
S. M. Weber, A. L. Scarim, and J. A. Corbett
PPAR{gamma} is not required for the inhibitory actions of PGJ2 on cytokine signaling in pancreatic {beta}-cells
Am J Physiol Endocrinol Metab, March 1, 2004; 286(3): E329 - E336.
[Abstract] [Full Text]


Home page
Clin. Cancer Res.Home page
T. Kumagai, T. Ikezoe, D. Gui, J. O'Kelly, X.-J. Tong, F. J. Cohen, J. W. Said, and H. P. Koeffler
RWJ-241947 (MCC-555), A Unique Peroxisome Proliferator-Activated Receptor-{gamma} Ligand with Antitumor Activity against Human Prostate Cancer in Vitro and in Beige/Nude/ X-Linked Immunodeficient Mice and Enhancement of Apoptosis in Myeloma Cells Induced by Arsenic Trioxide
Clin. Cancer Res., February 15, 2004; 10(4): 1508 - 1520.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
A. Mouihate, L. Boisse, and Q. J. Pittman
A Novel Antipyretic Action of 15-Deoxy-{Delta}12,14-Prostaglandin J2 in the Rat Brain
J. Neurosci., February 11, 2004; 24(6): 1312 - 1318.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. Perez-Sala, E. Cernuda-Morollon, and F. J. Canada
Molecular Basis for the Direct Inhibition of AP-1 DNA Binding by 15-Deoxy-{Delta}12,14-prostaglandin J2
J. Biol. Chem., December 19, 2003; 278(51): 51251 - 51260.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
B. Zingarelli, M. Sheehan, P. W. Hake, M. O'Connor, A. Denenberg, and J. A. Cook
Peroxisome Proliferator Activator Receptor-{gamma} Ligands, 15-Deoxy-{Delta}12,14-Prostaglandin J2 and Ciglitazone, Reduce Systemic Inflammation in Polymicrobial Sepsis by Modulation of Signal Transduction Pathways
J. Immunol., December 15, 2003; 171(12): 6827 - 6837.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
A. L. Scarim, S. Y. Nishimoto, S. M. Weber, and J. A. Corbett
Role for c-Jun N-Terminal Kinase in {beta}-Cell Recovery from Nitric Oxide-Mediated Damage
Endocrinology, August 1, 2003; 144(8): 3415 - 3422.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
S. M. Weber, A. L. Scarim, and J. A. Corbett
Inhibition of IFN-gamma -induced STAT1 activation by 15- deoxy-Delta 12,14-prostaglandin J2
Am J Physiol Endocrinol Metab, May 1, 2003; 284(5): E883 - E891.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Nencioni, F. Grunebach, A. Zobywlaski, C. Denzlinger, W. Brugger, and P. Brossart
Dendritic Cell Immunogenicity Is Regulated by Peroxisome Proliferator-Activated Receptor {gamma}
J. Immunol., August 1, 2002; 169(3): 1228 - 1235.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
N. Khandoudi, P. Delerive, I. Berrebi-Bertrand, R. E. Buckingham, B. Staels, and A. Bril
Rosiglitazone, a Peroxisome Proliferator-Activated Receptor-{gamma}, Inhibits the Jun NH2-Terminal Kinase/Activating Protein 1 Pathway and Protects the Heart From Ischemia/Reperfusion Injury
Diabetes, May 1, 2002; 51(5): 1507 - 1514.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. G. Harris, R. S. Smith, and R. P. Phipps
15-Deoxy-{Delta}12,1412,14-PGJ2 Induces IL-8 Production in Human T Cells by a Mitogen-Activated Protein Kinase Pathway
J. Immunol., February 1, 2002; 168(3): 1372 - 1379.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
B. H. ROVIN, L. LU, and A. COSIO
Cyclopentenone Prostaglandins Inhibit Cytokine-Induced NF-{kappa}B Activation and Chemokine Production by Human Mesangial Cells
J. Am. Soc. Nephrol., August 1, 2001; 12(8): 1659 - 1667.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
K. Guyton, R. Bond, C. Reilly, G. Gilkeson, P. Halushka, and J. Cook
Differential effects of 15-deoxy-{Delta}12,14-prostaglandin J2 and a peroxisome proliferator-activated receptor {gamma} agonist on macrophage activation
J. Leukoc. Biol., April 1, 2001; 69(4): 631 - 638.
[Abstract] [Full Text]


Home page
Clin. Chem.Home page
C. Thevenon, M. Guichardant, and M. Lagarde
Gas Chromatographic-Mass Spectrometric Measurement of 15-Deoxy-{{Delta}}12,14-prostaglandin J2, the Peroxisome Proliferator-activated Receptor {{gamma}} Ligand, in Urine
Clin. Chem., April 1, 2001; 47(4): 768 - 770.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
H. Ghanim, R. Garg, A. Aljada, P. Mohanty, Y. Kumbkarni, E. Assian, W. Hamouda, and P. Dandona
Suppression of Nuclear Factor-{{kappa}}B and Stimulation of Inhibitor {{kappa}}B by Troglitazone: Evidence for an Anti-inflammatory Effect and a Potential Antiatherosclerotic Effect in the Obese
J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1306 - 1312.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
T. Tanaka, H. Kohno, S.-i. Yoshitani, S. Takashima, A. Okumura, A. Murakami, and M. Hosokawa
Ligands for Peroxisome Proliferator-activated Receptors {{alpha}} and {{gamma}} Inhibit Chemically Induced Colitis and Formation of Aberrant Crypt Foci in Rats1
Cancer Res., March 1, 2001; 61(6): 2424 - 2428.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2000 by the American Diabetes Association.